spacer
home > ict > spring 2020 > role of comparators in clinical trial designs
PUBLICATIONS
International Clinical Trials

Role of Comparators in Clinical Trial Designs




Case studies provide real insight in how to choose comparators for rare diseases and oncology studies. Drug development is a very complex, long, and expensive process. Once a suitable molecule is identified, then clinical trials are undertaken to establish the effect of an intervention.

Treatment effects are efficiently isolated by controlling for bias, and confounding and minimising variation. Key features of clinical trials that are used to meet this objective are randomisation (possibly with stratification), adherence to intent-to-treat principles, blinding, prospective evaluation, and use of a control group. Compared to other types of study designs (e.g., casecontrol studies, cohort studies, and case reports), randomised trials have high validity, but are more difficult and expensive to conduct.

The gold standard of any scientific evidence is data generated from a randomised control trial. In these studies, a pool of patients is randomly assigned to two groups that receive different treatment. An experimental group will receive the investigational medicinal product (IMP) and a control group can receive a range of different interventions. The most commonly utilised are a placebo (an inert compound that has no effect on the endpoints measured) and an active comparator (usually the standard of care [SOC]) for the indication being tested for. The choice of medication for the control group depends on the nature of the disease. For example, oncology patients are always put on medication for ethical reasons.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Dr Vanessa Dekou, Managing Director, Clinical Services International (CSI) has extensive experience in drug development from preclinical to registration and commercialisation strategies and has secured product registration for several orphans and first-in-class drugs. She has successfully designed and executed numerous trials all over the world. As such, Vanessa understands all the challenges and requirements of supplying comparators to clinical trials and ensuring trials are delivered on time and on budget. Vanessa has worked with some of the largest biopharmaceutical and biotechnology companies to provide innovative solutions. At CSI, Vanessa is responsible for providing bespoke solutions to their clients to ensure comparator sourcing is not a rate-limiting step in the successful delivery of trials. She also works closely with pharma manufacturers to safeguard the supply chain and remain on the front line of advances in drug development. Vanessa has a PhD in Cardiovascular Genetics from University College of London, UK, an MBA from Cambridge, UK and a Masters in Market Access from University of Lyon, France.
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth

 PE overhang to fuel CDMO valuations and expansions, while VC overhang will fuel continued demand for services in spite of adverse global conditions
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement